文献速递精神分裂症与精神病性障碍心境障碍

英格兰新冠疫苗接种推广期间及之后严重精神疾病患者感染SARS-CoV-2后死亡率不平等:一项回顾性全国联动队列研究

Inequalities in mortality following SARS-CoV-2 infection for people with severe mental illness during and following vaccination roll-out in England: a retrospective, whole-country linked cohort study.
PubMed 文献 · Lancet Psychiatry · 2026-01-01

该回顾性全国联动队列研究分析英格兰2020年1月31日至2023年6月30日新冠感染者电子健康记录,比较严重精神疾病(SMI)与非SMI患者全因及新冠死亡率。

核心结论

  • SMI患者感染SARS-CoV-2后超额死亡风险贯穿整个新冠大流行阶段,疫苗接种仅部分减弱新冠死亡风险差异。

研究设计与样本

  • 回顾性全国联动队列研究,分析英格兰2020年1月31日至2023年6月30日新冠感染者电子健康记录,SMI定义包括精神分裂症、分裂情感性障碍、双相障碍或其他伴精神病性症状的心境与非心境障碍。

临床怎么用

  • 临床应关注SMI患者感染新冠后的超额死亡风险,并针对该群体加强疫苗接种和预防性公共卫生策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: People with severe mental illness (SMI) had a higher risk of death following SARS-CoV-2 infection compared with people without SMI during the COVID-19 pandemic peak. It is unclear whether this risk reduced in later stages after vaccination roll-out. We aimed to assess all-cause and cause-specific mortality following SARS-CoV-2 infection in people with or without SMI across pandemic stages, using whole-country data, while accounting for sociodemographic and clinical characteristics. METHODS: In this retrospective, whole-country cohort study, we analysed linked electronic health records for all people in England registered to primary care who were alive in November, 2019 (>99% of the population). The study population included people who had COVID-19 between Jan 31, 2020, and June 30, 2023, with information on deaths and vaccination. Data extracted from the NHS England Secure Data Environment provided through the British Heart Foundation Data Science Centre CVD-COVID-UK-COVID-IMPACT Consortium linked datasets were curated to form a dataset in July, 2024. Cox regression estimated differences in all-cause and COVID-19 mortality. Analyses were stratified by pandemic stages, defined by WHO policy and UK Government vaccination roll-out: Jan 31-Sept 30, 2020 (stage 1); Oct 1, 2020-July 18, 2021 (stage 2, vaccination roll-out); and July 19, 2021-June 30, 2023 (stage 3, post-vaccination roll-out). SMI comprised schizophrenia, schizoaffective disorder, bipolar disorder, or other affective and non-affective disorder with psychosis. A patient and public involvement panel was consulted during design phases of the study. FINDINGS: 13 463 945 people with COVID-19 were identified, of whom 160 190 (1·19%) had SMI. People with SMI were older [mean age [SD], SMI 49·7 years [17·9], non-SMI 45·0 years [17·6]), had a similar sex split (females SMI vs non-SMI: 56·3% vs 56·6%); and were mostly White British (77·3% or 76·3%). People with SMI had higher all-cause mortality than those without (adjusted hazard ratio [aHR] 1·56, 95% CI 1·53-1·59). All-cause mortality risk in people with SMI was elevated in stage 1 (aHR 1·27, 95% CI 1·22-1·32), but larger in the stage 2 (aHR 1·56, 1·51-1·61) and stage 3 (aHR 1·55, 1·50-1·59). Vaccination prevalence was initially higher for people with SMI (in stage 2: 112 795 [73·2%, 95% CI 72·9-73·4], compared with people without SMI, 8 852 970 [67·4%, 67·3-67·4]). By study end, fewer people with SMI were fully vaccinated (127 145 [79·4%, 79·2-79·6]), compared with people without SMI (11 605 915 [87·2%, 87·2-87·3]. Higher COVID-19 mortality risk in people with SMI persisted but was partially attenuated by vaccination (aHR 1·25, 1·17-1·34). INTERPRETATION: Excess mortality in people with SMI persisted throughout the COVID-19 pandemic. Preventive public health and clinical strategies are needed to address excess mortality and lower vaccination. FUNDING: Health Foundation-Academy of Medical Sciences.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Chilman N, Bécares L, Dregan A, et al. Inequalities in mortality following SARS-CoV-2 infection for people with severe mental illness during and following vaccination roll-out in England: a retrospective, whole-country linked cohort study. Lancet Psychiatry. 2026. PMID: 42586081. doi:10.1016/S2215-0366(26)00195-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。